RxDoctor Payments Data

Destry Elms, MD

Hematology & Oncology · Maywood, ILNPI 1992236996

Payments from drug & device makers

$336,569in general payments, 2019–2025

Across 330 payments — averaging $1019.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beone Medicines Ltd.$252K
  • E.r. Squibb & Sons, L.L.C.$33K
  • Daiichi Sankyo Inc.$21K
  • Janssen Research & Development, LLC$10K
  • Epizyme, Inc.$8K
  • Pfizer$3K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$9,30396%
  • Education$3494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Beone Medicines Ltd.2$251,520
E.r. Squibb & Sons, L.L.C.20$33,142
Daiichi Sankyo Inc.13$21,135
Janssen Research & Development, LLC3$10,269
Epizyme, Inc.9$7,527
Pfizer25$3,488
Genentech, Inc.1$1,375
Sanofi9$764
Incyte Corporation12$514
AbbVie18$478
Bristol Myers Squibb11$471
Novartis20$437
Exelixis Inc.4$355
Takeda Pharmaceuticals U.S.A., Inc.9$354
AstraZeneca(2 entities)12$314
Johnson & Johnson12$269
Astellas Pharma US Inc9$264
Regeneron Healthcare Solutions, Inc.6$248
Genentech USA, Inc.9$215
Gilead(2 entities)9$205
Agios Pharmaceuticals, Inc.4$193
Seagen Inc.4$192
Eisai Inc.8$190
Merck7$175
Bayer7$173
Octapharma USA, Inc.1$150
GSK8$146
ADC Therapeutics America, Inc.2$144
Jazz Pharmaceuticals Inc.4$132
Pharmaessentia USA Corporation4$111
Servier Pharmaceuticals LLC4$96
Tersera Therapeutics LLC3$91
Beigene USA, Inc.4$90
Array Biopharma Inc3$84
AVEO Pharmaceuticals, Inc.3$77
Blueprint Medicines Corporation3$72
Stemline Therapeutics Inc.3$71
Lilly USA, LLC3$67
EMD Serono, Inc.3$66
Pharmacosmos Therapeutics Inc.3$66
Sobi, Inc3$61
Springworks Therapeutics, Inc.2$59
Boehringer Ingelheim2$58
Syndax Pharmaceuticals, Inc.2$57
Amneal Pharmaceuticals LLC2$50
Mirati Therapeutics, Inc.2$49
Adaptive Biotechnologies Corporation2$46
Apellis Pharmaceuticals, Inc.2$45
Genmab U.S., Inc.2$41
Puma Biotechnology, Inc.2$36
Rigel Pharmaceuticals, Inc.2$36
Karyopharm Therapeutics Inc.2$36
Fresenius Kabi USA, LLC1$33
Beone Medicines USA, Inc.1$32
Deciphera Pharmaceuticals Inc.1$30
Dendreon Pharmaceuticals LLC1$25
G1 Therapeutics, Inc.1$23
Mylan Institutional Inc.1$22
Taiho Oncology, Inc.1$21
Immunocore Limited1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$336,569 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,316,193
Medicare patients
413
Services billed
73,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide28$412,527
PomalystPomalidomide12$174,457
ErleadaApalutamide12$169,495
BrukinsaZanubrutinib13$157,554
JakafiRuxolitinib Phosphate12$95,548
EliquisApixaban35$48,638
PromactaEltrombopag Olamine12$47,828
Abiraterone Acetate23$9,098
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$821
Prochlorperazine Maleate20$452
Hydroxyurea16$385
Gabapentin18$322
Mirtazapine21$320
Acyclovir29$236
Dexamethasone22$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$471$412,52728 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$33,142$174,45712 claims
Johnson & JohnsonErleada$269$169,49512 claims
Beigene USA, Inc.Brukinsa$90$157,55413 claims
Incyte CorporationJakafi$514$95,54812 claims
PfizerEliquis$3,488$48,63835 claims
NovartisPromacta$437$47,82812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →